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ABSTRACT 
 
Background: The problem of obesity in the adult population requires the 
exploration and development of new, safe effective therapies to combat 
increasing girth. Implantable gastric electrical stimulation (GES) offers a novel, 
minimally invasive surgical approach to promote weight loss. This report utilizes 
the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) tool to review and evaluate current literature exploring GES as a safe 
and effective therapy for reducing obesity in adults. 
 
Method: An exhaustive search of available medical literature was conducted in 
the PubMed, Medline, Evidence-Based Medicine Reviews Multifile, Web of 
Science, and CINHAL databases. 
 
Results: Three studies were reviewed for the primary endpoint of percentage of 
excess weight loss (EWL) and secondary endpoint of device safety. GRADE 
results revealed moderate levels of evidence for both of these endpoints. A small 
subset of adult patients experienced weight loss ranging between 5-17% EWL 
while other patients experienced weight gain. 
 
Conclusion: Use of a gastric electrical stimulation device fails to produce any 
significant weight loss in obese individuals when compared to traditional lifestyle 
changes of diet and exercise. Implantable GES for weight loss in obese adults is 
not recommended. 
 
Keywords: Gastric electrical stimulation, gastric pacing, adult, obesity and weight 
loss 
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INTRODUCTION 
Background 
 Obesity is a growing pandemic, tipping scales across the globe. The most 
current statistics from the International Association for the Study of Obesity 
(IASO, 2010) estimate that worldwide over 475 million people are obese. The 
Centers for Disease Control and Prevention (CDC, 2010) report that in the United 
States approximately 72.5 million adults are obese. This translates into greater 
than one in three American adults having a body mass index (BMI) > 30 kg/m2 
(Bray, 2011; Flegal, Carroll, Ogden, & Curtin, 2010; Appendix A, Table 1). 
 Obesity takes is toll both directly through economic costs and rising rates 
of morbidity and mortality and indirectly through non-tangible drains on society. 
The annual medical burden of obesity is estimated to be $147 billion per year 
with a per capita spending 42% higher than for someone of normal weight 
(Finkelstein, Trogdon, Cohen, & Dietz, 2009). The IASO (2010) reports that 
increased BMI has been strongly linked as a risk factor for the development of 
type II diabetes, hypertension, coronary-heart disease, and other co-morbidities 
such as various cancers, gall-bladder disease, fatty liver, sleep apnea and 
osteoarthritis. The organization also reports that annually, obesity is responsible 
for an estimated 2.8 million unnecessary deaths in the US. Obesity is now 
considered to be at least equal to smoking as a preventable cause of premature 
death (Monash University, 2009). In the Framingham Study, obese middle aged 
adults lived on average six to seven years less than those with BMI < 24.9 kg/m2 
(Bray, 2011). Conversely, by maintaining a healthy BMI of less than 30 kg/m2 a 
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middle aged adult would gain about two years of life expectancy (Prospective 
Studies Collaboration, 2009). Obesity also indirectly puts a strain on social 
resources by forcing numerous infrastructure changes including but not limited to 
wider transportation seats, reinforced hospital beds and larger wheelchairs. 
Furthermore, income lost from absenteeism, decreased productivity and illness is 
often overlooked when evaluating the overall negative impact of obesity within 
America (IASO, 2010). In 2004, disability attributable to obesity was calculated at 
over 36 million disability-adjusted life years (IASO, 2010). It is clear that the 
socioeconomic hardships stemming from obesity require immediate attention. 
 Despite available anti-obesity treatment options such as behavioral, 
pharmaceutical or surgical interventions, rates of obesity have increased 1.1 
percentage points since 2007 (CDC, 2010). Conservative lifestyle alterations 
such as diet and exercise are proving to be insufficient in combating obesity, so 
long-term maintenance of weight loss remains uncommon (Hogan, Gallagher, 
Kennelly, Baird, & Winter, 2009). Furthermore, systematic reviews of oral weight 
loss drugs show poor compliance and minimal weight loss after one year of 
treatment (Hogan et al., 2009). Finally, while surgical interventions are 
moderately successful, currently <1% of patients who qualify for bariatric surgery 
will undergo it (Shikora, 2004). Obstacles to bariatric operations include large 
financial cost and patient fear of perioperative and long-term complications. 
Morbidly obese individuals are often coupled with multiple comorbidities making 
them high-risk surgical candidates. The death rate for bariatric procedures 
ranges between 0.2%-1% with a ten-fold major complication rate of about 10-
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20% (Shikora, 2004). The continuing trend toward an increasing adult BMI 
reflects an urgent need for more affordable, more effective and overall safer 
bariatric treatment alternatives. 
 One such promising alternative is the implantable gastric stimulation 
device. Shown to be effective in animal trials as well as some small human trials, 
this bariatric surgery is being touted as the safest and simplest operation 
currently available (Bohdjalian et al., 2006; Greenway & Zheng, 2007). Unlike 
other obesity surgeries, gastric electrical stimulation (GES) does not rely on 
manipulation and rearrangement of the patient’s anatomy to promote 
malabsorption or create restrictive conditions in order to achieve weight loss. 
Instead, GES applies a small electric current to stimulate the stomach and induce 
early satiety while reducing appetite (Hogan et al., 2009). The GES device 
consists of an electrical pulse generator similar to a cardiac pacemaker and 
bipolar leads (Shikora et al., 2004; Appendix B, Figure 1). A minimally invasive 
laparoscopic technique implants these electrode leads in the gastric muscular 
wall, while the generator is implanted subcutaneously along the anterior 
abdomen (Sanmiguel et al., 2009). Post-operatively, the device is turned on and 
rhythmic imperceptible contractions commence. Variations among devices exist, 
as currently there is no standardized anatomic position for lead placement nor is 
there a uniform recommendation for stimulation voltage, pulse width, pulse 
frequency, or duty cycle. 
 A systematic review of GES as a treatment for morbid obesity was 
performed in 2006 (Medical Advisory Secretariat, 2006). The authors found the 
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quality of evidence to be low and gave a weak recommendation for using GES to 
treat morbid obesity in adults. At that time, no randomized clinical trials had been 
published in full. Since 2006, new literature has emerged further evaluating this 
unique approach as a treatment for adult obesity. 
Purpose of the Study 
The purpose of this paper is to perform a systematic review of the most 
recent literature published after 2006, to evaluate the safety and efficacy of 
implantable gastric stimulation to reduce obesity in adult patients. The literature 
will be evaluated using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) tool developed by the GRADE Working 
Group. 
METHOD 
 
An extensive literature search was performed using PubMed, Medline, 
Evidence-Based Medicine Reviews Multifile, Web of Science and CINHAL. 
These databases were accessed through the Pacific University Library system. 
The following keywords were searched individually and in combination: gastric 
electrical stimulation, gastric pacing, adult, obesity and weight loss. The search 
was limited to human subjects, the English language and articles published after 
2006. The initial results included 37 articles of which duplicates, descriptive 
reviews and letters to the editor were excluded. This resulted in 26 articles to 
review. Articles which did not examine weight loss as a primary outcome of 
interest, studies that included participants with poorly controlled diabetes, or 
studies with participants who had failed previous bariatric surgery were excluded. 
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This left three relevant articles which met inclusion criteria and were assessed in 
the final analysis. 
RESULTS  
The first study reviewed was performed by Shikora et al. (2009) who 
conducted a large, randomized, placebo-controlled, double-blind, multi-center 
study known as the SHAPE trial, with a primary outcome of evaluating the 
difference in the percentage of excess weight loss (EWL) between control and 
treatment groups. The SHAPE trial was sponsored by Medtronic/Transneuronix, 
the manufacturers of the Transcend implantable GES device (Shikora et al., 
2009). Enrollment criteria were limited to adult participants (18-65 years old) with 
a BMI of 35-55 kg/m2 and who have successfully passed a BaroScreen screening 
algorithm. This algorithm was developed by Medtronic of Minneapolis, MN using 
data gathered from previous gastric stimulation clinical studies as a predictive 
tool to estimate potential weight loss with implantable GES treatment. Only 
candidates with a predicted loss of > 15% excess body weight within one year 
were considered eligible for enrollment in the trial. Exclusion criteria included 
pregnancy, lactation, previous gastrointestinal (GI) bariatric surgery, previous 
operations of any type on the stomach, the presence of other electrostimulation 
devices, GI motility disorders, peptic ulcer disease, behavioral issues that would 
have excluded them from conventional bariatric surgery, binge eaters, and 
clinically important co-morbid diseases such as poorly controlled diabetes.  
In all, 190 patients underwent implantation with the Transcend gastric 
stimulation device (Shikora et al., 2009; Appendix C, Figure 2). Two weeks after 
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implantation, randomization occurred. At this point one half of the study 
population had their stimulation device turned on while the other half was kept 
inactive. “All subjects were instructed to consume a diet with a 500-kcal/d deficiet 
and were required to attend monthly support group meetings” (Shikora, et al. 
2009, p. 445). After 12 months of treatment there was no statistically significant 
difference in the percentage of excess weight loss between the treatment and 
control groups. Additionally, there were no statistically significant between-group 
differences at any month during the trial. At the conclusion of the 12 month 
period the control group lost 11.7% + 16.9% of their excess weight and the 
treatment group lost 11.8% + 17.6% of their excess weight. The authors 
concluded that no clinically or statistically significant difference for the primary 
outcome of weight loss was found between the two groups in the study. They go 
on to state that these findings are consistent with those achieved in earlier trials 
evaluating implantable GES for the treatment of obesity in adults (Shikora et al., 
2009). 
Beyond evaluating the efficacy of GES as a treatment for obesity, a 
secondary outcome of the SHAPE trial assessed the safety of the device. Of the 
190 subjects, 26 (13.7%) experienced one or more endoscopy-detected gastric 
lumen lead penetrations during the laparoscopic implantation. None of these 
perforations led to consequences such as gastric leak, infection, or bleeding. 
Additional complications included two lead dislodgments and one patient who 
developed a pocket infection. Also, at the conclusion of the study it was 
discovered that 22 devices were noted to have a low battery capacity. Despite 
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these incidents, no deaths or major complications occurred. Given these results, 
the authors concluded that implantable gastric stimulation is a less complex 
procedure than current bariatric operations. 
The second study reviewed also evaluated weight loss and safety 
outcomes of GES. Performed by Champion, Williams, Champion, Gianos, and 
Carrasquilla (2006), a small, nonrandomized, open-label FDA clinical trial 
evaluated the safety and efficacy of GES in low BMI patients. The primary 
outcome of interest was 10% total body weight loss within the 2-year follow-up 
period. Secondary outcomes included monitoring of adverse outcomes and 
change in waist circumference. Inclusion criteria were adult patients, a BMI 
between 30-35 kg/m2, passing a BaroScreen algorithm, passing a binge eating 
questionnaire, and a psychological evaluation. No exclusion criteria were 
reported. 
In all, 24 patients at two geographic sites underwent laparoscopic 
implantation of the Transcend gastric stimulation device (Champion, Williams, 
Champion, Gianos, & Carrasquilla, 2006). Two weeks after surgery all of the 
devices were activated. The participants were instructed on a 500-calorie energy-
deficient diet and exercise program. Follow-up findings and outcomes at six 
months were reported. The mean percentage of EWL at six months for the 
combined 24 patients was 5.9% total. A subset of nine patients had an EWL of at 
least 10% (mean 20.1% EWL). In total, 14 patients lost weight (mean 13.9% 
EWL) and 10 patients gained weight (mean 8.2% estimated weight gain). There 
were no deaths or serious adverse events reported by the authors. Adverse 
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events reported for more than 5% of subjects included abdominal pain (20.8% 
incidence), incisional site pain (16.7%), stomach lumen penetration at implant 
(16.7%), generalized pain (12.5%), fever (8.3%) and flatulence (8.3%). The only 
statistically significant outcome reported in the study, was a mean waist 
circumference decrease of 5.8%. The authors concluded that gastric stimulation 
appears to be safe for weight loss in a low BMI population. Since only 
approximately one-third of the patients experienced an EWL exceeding 10% at 
six months, the authors felt further exploration of GES is warranted. 
The third and final study reviewed was by Bohdjalian et al. (2006) which 
explored the effect GES had on several outcomes. The article described a small, 
prospective, non-randomized, open-label, single-center trial which evaluated 
changes in body weight in morbidly obese human subjects, gastric stimulation 
device safety, and the effect of GES on both eating behavior and blood pressure. 
The participants were followed over a 20 week period with an additional 
extension period up to 52 weeks. Inclusion criteria consisted of adult patients 
between 18-50 years of age, a BMI between 35-50 kg/m2 which had been stable 
for three months, five years of obesity history and energy expenditure > 1200 
kcal/day. Participants were excluded from the study if they had had a previously 
placed permanent electro-stimulation device, undergone previous bariatric 
surgery, were found to have unstable weight (+ 1 BMI unit) during the four week 
screening period, were currently taking antidepressant drugs, had an eating 
disorder, had endocrine-related obesity, had taken weight-loss medication within 
the last three months, suffered from motility disorders of the GI tract, had an 
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alcohol or drug abuse problem, or suffered from any psychopathological 
diseases. 
In all, 12 morbidly obese, non-diabetic subjects were included in the 
Bohdjalian et al. (2006) study and were laparoscopically implanted with the 
TantalusTM System (Appendix D, Figure 3). After a six week stabilization period 
following device implantation, all devices were activated. While the participants 
were not required to follow a specific diet, a dietician did provide information 
about the caloric content of foods and education about a healthy diet. The 
authors reported that at 20 weeks a statistically significant body weight decrease 
from 128.8 kg + 5.2 kg to 119.9 kg + 5.9 kg corresponding to an EWL of 17.6% + 
4.3% occurred. At 28 weeks, three patients had dropped out of the study. In the 
remaining nine subjects a further decrease to 112.4 kg + 3.8 kg was observed, 
corresponding to an excess weight loss of 26.6% + 8.5%. At the conclusion of 
the study, after a 52-week period and one further drop out, a total EWL of 30.5% 
+ 8.5% was documented in the remaining eight participants. The authors 
concluded that weight loss achieved via gastric stimulation is comparable to 
gastric banding over a 52 week period but inferior to gastric bypass and other 
malabsorptive procedures. It was the authors’ opinion that these results for 
weight loss encourage further studies so that GES may eventually be included 
among the options for the treatment of obesity. 
Secondary outcomes of the study included the effect implantable GES had 
on blood pressure (BP) and eating behavior. Device safety was also examined 
(Bohdjalian et al., 2006). In regards to blood pressure, the authors found a 
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statistically significant decrease at week 20 and again at one year follow-up 
readings. The mean BP of 10 participants decreased from 142mmHg + 6.1 / 
91mmHg + 3.2 to 125.5mmHg + 4.0 / 83mmHg + 2.6 at week 20 and the mean 
BP of eight participants was 128.8mmHg + 3.8 / 86.3mmHg + 3.6 at one year. In 
regards to eating behavior, the authors state “subjects showed a significant 
reduction in the score for hunger, while the score for cognitive control increased 
significantly” (Bohdjalian et al., 2006, p. 631). Safety concerns associated with 
the device or procedure were minimal. There were five documented lead failures 
in four patients and one intra-operative gastric penetration. One serious adverse 
event related to the surgery, was the development of severe rhabdomyolysis and 
blood loss in combination with pulmonary insufficiency on the day of implantation 
leading to prolonged hospitalization. Though attributed to the procedure, the 
events resolved without sequelae and the participant was able to complete the 
study. No other safety concerns related to the device or its implantation were 
cited. Altogether, the authors concluded, “that the device and its implantation 
appear to be safe and well-tolerated” (Bohdjalian et al., 2006, p. 632). 
DISCUSSION 
A need to develop efficient and effective alternatives to bariatric surgery 
exists if there is any hope of reversing rising obesity trends in the US. Gastric 
electrical stimulation offers a novel approach to treating obesity in adults. The 
procedure is minimally invasive, reversible and does not alter existing GI 
anatomy. Review of the evidence revealed that a small subset of obese adults 
treated with an implantable gastric stimulation device successfully achieved 
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between 5% and 17% excess weight loss at the conclusion of the studies. 
However, this EWL range is similar to that achieved by diet and exercise alone in 
the SHAPE trial (Shikora et al., 2009). Furthermore, some patients either failed to 
lose weight or gained weight after implantation with GES (Champion et al., 
2006). The GES devices appear to be both safe to implement and well tolerated 
without any reported deaths and few serious adverse effects. While these results 
seem promising, there were several important methodological flaws in the three 
studies reviewed. 
The randomized controlled trial (RCT) performed by Shikora et al. (2009) 
is the first of its kind to explore, in a double-blind, placebo-controlled fashion, the 
applications of GES in obese subjects. Overall, the study was of excellent quality 
with only a small number of drawbacks. Limitations to this study consist of 
applicability to all adult populations, possible device battery failure and potential 
publication bias. Of the 190 study participants 81.6% were of Caucasian race 
and 87.4% were female. It is possible that the primary outcome of weight loss 
would be different when evaluated in other ethnicities or in equal gender 
proportions. Secondly, at the conclusion of the 12 month trial period it was 
discovered that 22 participants had devices which read “low battery capacity.” All 
of these subjects were allocated to the treatment group which means that for an 
unspecified period of time some of the device batteries were exhausted. It is 
unknown whether these participants may have achieved greater weight loss had 
gastric stimulation been occurring as intended. The authors did not re-evaluate 
the raw data after excluding these 22 subjects from statistical analysis. Lastly, 
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the SHAPE trial was sponsored by Medtronic/Transneuronix, the manufacturers 
of the Transcend device (Shikora et al., 2009). This sponsor compiled the raw 
data, analyzed the data, and produced data summaries which have the potential 
of researcher bias. However, the data was available to all authors upon request 
and the final report was reviewed and approved by all co-authors (Shikora et al., 
2009). 
Limitations to the Champion et al. (2006) study included a small sample 
size of 24 subjects, diminished applicability of GES for males as 87.5% (21 of the 
participants) were female and selection bias. The patients self-selected to 
participate in this open-label, non-randomized, and un-blinded study. Also 
beyond asserting that the patients were similar with regards to age, baseline 
weight and BMI, no further comorbidities were addressed by the authors. Another 
limitation included the short follow-up period. The primary outcome was to 
address total body weight loss after two years yet the trial was stopped early for 
unstated reasons and only data at the six month endpoint is reported. Moreover, 
three out of the 24 patients were dropped from the study prior the six-month visit 
and their final weights were not obtained. Finally, the authors did not supply raw 
data for the changes in waist circumference which was the only statistically 
significant finding in the study. Instead, the authors generalize that “the mean 
waist circumference decreased 5.8%” (Champion et al., 2006, p. 444). 
Limitations to the third and final study by Bohdjalian et al. (2006) included 
a small sample size of 12, the short amount of time that all participants were 
being stimulated and evaluated, and a large loss to follow up at the 52 week 
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mark. The authors go on to state “the study was further limited by the absence of 
subject and investigator blinding, a control group or the use of a cross-over 
design” (Bohdjalian et al., 2006, p. 633). Moreover, the authors did not publish 
any raw data. They instead reported their results in terms of mean values which 
shows potential publication bias. Finally, it is unclear whether the observed blood 
pressure decrease is inferred by the authors to be a direct outcome from the 
gastric stimulation device or if is secondary to weight loss. 
To evaluate the evidence presented by these three articles in an explicit, 
comprehensive and systematic fashion we employed the GRADE system, 
developed by the GRADE Working Group, which rates both the quality of 
evidence and the strength of recommendation (Guyatt et al., 2008). Quality of 
evidence is classified as either high, moderate, low, or very low. High quality 
evidence means that further research is very unlikely to change the confidence in 
the estimate of effect. Moderate quality signifies that further research is likely to 
impact confidence in the estimate and may change the estimate while low quality 
signifies that further research is very likely to impact confidence in the estimate 
and is likely to change the estimate. Very low quality of evidence means that any 
estimate of effect is very uncertain (Guyatt et al., 2008, p. 926). Randomized 
controlled trials begin as high quality of evidence but can be downgraded based 
on study limitations, inconsistency of results, indirectness of evidence, 
imprecision in estimates, or high likelihood of publication bias. On the other hand, 
observational studies start as low quality of evidence but can be upgraded if the 
magnitude of the treatment effect is large, if there is evidence of a dose-response 
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gradient, or if plausible biases which could diminish the effect of the intervention 
are identified. 
A second purpose of the GRADE tool is to evaluate the strength of the 
recommendation. A strong recommendation is made when it is very certain that 
the desirable effects of an intervention outweigh risks and burdens. Strong 
recommendations imply that virtually all informed patients will make the same 
choice. A weak recommendation is given when risks and burdens are balanced 
against desired effects or when there is appreciable uncertainty about the 
magnitude of benefits and risks. Weak recommendations imply that patient 
values and preferences play a crucial role in individual decisions (Guyatt et al., 
2008). 
After applying GRADE to the three articles evaluating weight loss in obese 
adult patients using gastric electrical stimulation, the GRADE for this outcome is 
moderate and the strength of the recommendation is weak (Appendix E, Table 
2). The single RCT performed by Shikora et al. (2009) was a well designed, 
precise study that produced results consistent with previous reports. Although 
there were limitations noted in the study, it was not felt that these limitations were 
significant enough to warrant downgrading the GRADE score of this RCT from 
high. The two observational studies however, were of low quality and unable to 
be upgraded. The patients had self-selected to participate in the open-label, non-
randomized and un-blinded studies. The sample sizes were small (n=36) and 
there was a large loss to follow up in both studies. No large magnitude of effect 
or dose-response gradient could be inferred from the results, thus the quality of 
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evidence could not be upgraded. The poor quality of the two observational 
studies combined with the existence of only one high quality RCT necessitates 
an overall GRADE of moderate for the body of evidence supporting the outcome 
of weight loss via GES.  
Applying the GRADE tool to evaluate gastric electrical stimulation device 
safety reveals that the quality of evidence is also moderate. Between the one 
RCT and the two observational studies, few serious adverse events were 
reported. This is consistent with previous findings that after implantation in over 
800 patients worldwide, “the operative procedure is relatively safe, simple, and 
devoid of any long-term nutritional or metabolic derangements” (Shikora et al., 
2009, p. 35). The RCT cannot be downgraded due to poor study quality, 
inconsistency, indirectness, imprecision, or publication bias, therefore, it remains 
at a GRADE of high. Conversely, the observational studies cannot have 
increased GRADE because there is no proof of a large magnitude of effect, a 
dose-response relationship, or the identification of any confounders responsible 
for the treatment effect so they remain low. Consequently, for the body of 
evidence supporting the outcome of GES device safety, an overall GRADE of 
moderate is reached.  
The overall GRADE of evidence for using an implantable gastric 
stimulation device to safely promote weight loss is moderate. At this time, there is 
only enough evidence to justify a weak recommendation for using GES to treat 
obesity in adults. Each study only saw a fraction of their participants lose weight 
and the SHAPE trial found no difference in weight loss between the control and 
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treatment groups. Across all three trials, several individuals saw either no weight 
loss or had weight gain at the end of the study period. Despite being safe and 
minimally effective for weight loss in a handful of study participants, the extent of 
EWL with GES is significantly below the effectiveness that bariatric surgeons 
have come to expect. Current bariatric surgery techniques such as lap banding, 
gastric sleeves, or Roux-en-Y procedures, on average, have a >50% EWL 
(Lanthaler et al., 2010; Schouten, Wiryasaputra, van Dielen, van Gemert, & 
Greve, 2010; Welch et al., 2011). In light of this standard, the results gleaned 
from the three studies reviewed are disappointing. Since the evidence implies 
some uncertainty about the benefits of implanting a gastric stimulation device for 
weight loss in obese individuals, it is suggested that clinicians continue to advise 
lifestyle changes, pharmacotherapy, or standard surgical approaches for weight 
loss. 
There are several factors revolving around GES which demand further 
exploration. For example, while it is hypothesized that GES functions by reducing 
appetite and increasing satiety, the exact mechanism of action remains unknown. 
Several study participants described increased feelings of fullness with GES, 
therefore, further evaluation of this type of device and its application towards 
reducing BMI should be pursued. Furthermore, technical aspects of both the 
Transcend and the Tantulus devices need to be improved upon. Creation of 
standard settings for electrical stimulation as well as standard lead placement 
sites on the gastric mucosa may improve results and reduce variability between 
 21 
study populations. It is likely that as additional RCT are performed and GES 
parameters are developed, EWL results beyond 17% could be seen. 
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APPENDIX A 
Table 1: Body Mass Index (BMI) Classification 
 
Classification BMI (kg/m2) 
 
Underweight 
 
 
< 18.5 
 
Normal weight 
 
 
> 18.5 – 24.9 
 
Overweight 
 
 
> 25.0 – 29.9 
 
Obese Class I 
 
 
> 30.0 – 34.9 
 
Obese Class II 
 
 
> 35.0-39.9 
 
Obese Class III 
(severe/extreme/morbid obesity) 
 
 
> 40.0 
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APPENDIX B 
 
Figure 1. Intra-operative view of implantable GES device during laparotomy with 
electrodes attached to the proximal antrum 
 
Reprinted from Gastroenterology Clinics of North America, Vol 36, Lin, K., 
Sarosiek, I., & McCallum R.W., Gastrointestinal electrical stimulation for 
treatment of gastrointestinal disorders: gastroparesis, obesity, fecal incontinence, 
and constipation, p. 723, (2007), with permission from Elsevier 
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APPENDIX C 
 
Figure 2. Transcend gastric electrical stimulation device and its anatomical 
placement 
 
Reprinted with kind permission from Springer Science and Business Media: 
Obesity Surgery Journal, Long-term follow-up of gastric stimulation for obesity: 
The Mestre 8-year experience, 14 (Suppl 1), 2004, S14-S22, Cigaina, V. 
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APPENDIX D 
 
Figure 3. TantulusTM Gastric Electrical Stimulation Device 
 
Reprinted with kind permission from Springer Science and Business Media: 
Obesity Surgery Journal, One-Year Experience with Tantalus: a New Surgical 
Approach to Treat Morbid Obesity, 16, 2006, 627-634, Bohdjalian et al., Figure 1. 
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APPENDIX E 
Table 2: GRADE Quality of Studies 
 
 
 
 
Decrease GRADE Increase 
GRADE 
Comparison Outcome Quantity 
and type 
of 
evidence 
Findings Starting 
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Grade of 
Evidence 
for 
Outcome 
Overall 
GRADE of 
Evidence 
High 0 0 0 0 0 0 0 0 High Weight 
Loss 
1 RCT 
2 Case 
series 
Equivalent 
weight 
loss Low 0 0 0 0 0 0 0 0 Low 
Moderate 
High 0 0 0 0 0 0 0 0 High 
Implantable 
Gastric 
Stimulation 
Device vs 
Standard 
Therapy 
Device 
Safety 
1 RCT 
2 Case 
series 
No 
serious 
adverse 
events 
Low 0 0 0 0 0 0 0 0 Low 
Moderate 
 
 
Moderate 
